Nishi, Kentaro
Uemura, Osamu
Harada, Ryoko
Yamamoto, Masaki
Okuda, Yusuke
Miura, Kenichiro
Gotoh, Yoshimitsu
Kise, Tomoo
Hirano, Daishi
Hamasaki, Yuko
Fujita, Naoya
Uchimura, Toru
Ninchoji, Takeshi
Isayama, Tetsuya
Hamada, Riku
Kamei, Koichi
Kaneko, Tetsuji
Ishikura, Kenji http://orcid.org/0000-0003-2692-6437
,
Funding for this research was provided by:
Childhood-onset, rare, and intractable kidney diseases in Japan, research on rare and intractable diseases, Health, Labour and Welfare Sciences Research Grants (20FC1028)
Article History
Received: 6 March 2022
Revised: 23 July 2022
Accepted: 25 July 2022
First Online: 11 August 2022
Declarations
:
: The study protocol was approved by the institutional ethics committee of the National Center for Child Health and Development (approval no. 2020–169). Study approval with agreement for data was shared among each institution’s ethics committee.
: Informed consent for participating in this study was not required in accordance with the Declaration of Helsinki and the Ethical Guidelines for Medical and Health Research Involving Human Subjects of the Ministry of Health, Labour, and Welfare. Consent for publication was waived in accordance with the guidelines.
: Kenji Ishikura has received research funding from the Asahi Kasei Pharma Corporation, Novartis International AG, Japan Blood Products Organization, Teijin Pharma Limited, JCR Pharmaceuticals Co., Ltd., Chugai Pharmaceutical Co., Ltd., Zenyaku Kogyo Co., Ltd., Otsuka Pharmaceutical Co. Ltd., Shionogi Co., Ltd., and The Morinaga Foundation for Health & Nutrition; and lecture fees from Asahi Kasei Pharma Corporation, Novartis International AG, Chugai Pharmaceutical Co., Ltd., Zenyaku Kogyo Co., Ltd., Otsuka Pharmaceutical Co. Ltd., Teijin Pharma Limited, Astellas Pharma Inc., Sanofi S.A., Pfizer Inc., AstraZeneca plc, and Miyarisan Pharmaceutical Co. Yusuke Okuda has received research funding from JSPS Kakenhi. Yuko Hamasaki has received lecture fees from Torii Pharmaceutical Co., Ltd and Pfizer Inc. Koichi Kamei has received research funding from the Terumo Foundation for Life Sciences and Arts, Public Foundation of Vaccination Research Center, and Taiju Life Social Welfare Foundation; donations from Chugai Pharmaceutical Co. Ltd., Astellas Pharma Inc., Ono Pharmaceutical Co., Teijin Pharma Ltd., Shionogi Co. Ltd., and Otsuka Pharmaceutical Co. Ltd.; and lecture fees from Tanabe Mitsubishi Pharma, Baxter Ltd., and Zenyaku Kogyo Co. Ltd. Other authors have no potential conflicts of interests to disclose.